Instil Bio
43 hedge funds and large institutions have $91.2M invested in Instil Bio in 2025 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
10% more funds holding
Funds holding: 39 → 43 (+4)
0.22% more ownership
Funds ownership: 80.21% → 80.44% (+0.22%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
9% less capital invested
Capital invested by funds: $100M → $91.2M (-$8.81M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.3M |
| 2 |
Millennium Management
New York
|
+$3.3M |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$1.43M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$403K |
| 5 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
+$388K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Boxer Capital Management
San Diego,
California
|
-$5.71M |
| 2 |
SCM
Superstring Capital Management
New York
|
-$2.83M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.53M |
| 4 |
6CM
683 Capital Management
New York
|
-$660K |
| 5 |
Renaissance Technologies
New York
|
-$598K |
TIL Hedge Fund Activity: Q1 2025 in Review
43 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q1 2025, worth a combined $91.2M — down 8.8% from $100M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TIL positions and 5 closed out — a net gain of 4 holders — while 11 added to existing stakes and 12 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $5.3M. The largest seller was Boxer Capital Management, cutting an estimated $5.71M.
- 43 institutional investors held Instil Bio (TIL) as of Q1 2025, up from 39 in Q4 2024.
- Funds reported $91.2M of Instil Bio stock for Q1 2025, down 8.8% quarter-over-quarter.
- 9 funds opened new Instil Bio positions in Q1 2025 and 5 closed out, a net change of +4 holders.
- The largest Instil Bio buyer in Q1 2025 was Balyasny Asset Management, an estimated $5.3M added.
- The largest Instil Bio seller in Q1 2025 was Boxer Capital Management, an estimated $5.71M sold.
Based on aggregated 13F filings for Q1 2025.